Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
InxMed (Shanghai) Co., Ltd.
NRG Oncology
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
NRG Oncology
Radiation Therapy Oncology Group
Innovent Biologics (Suzhou) Co. Ltd.
Sun Yat-sen University
Tianjin Medical University Cancer Institute and Hospital